Nanostructured in vitro TB latency model

纳米结构体外结核潜伏期模型

基本信息

  • 批准号:
    7876788
  • 负责人:
  • 金额:
    $ 22.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-06-19 至 2012-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Mycobacterium tuberculosis latently persist in 2 billion people, representing a major reservoir of tuberculosis (TB) due to reactivation, yet the state of latent bacilli remains a mystery. In order to eradicate TB, we need to understand latency and develop in vitro models for drug screening. In this interdisciplinary project we have merged microbiological tuberculosis research with nanotechnology and novel materials. Recent publications demonstrate a unique phenomenon of cell-directed assembly of hybrid lipid-inorganic nanostructures that drive a unique non-replicative persistence, and protect bacteria and drastically prolong viability. We show these same structures can be formed using mycobacteria, and that they display the highly extended viability characteristic of latency. We hypothesize that the persistence of latent TB, and its resistance to chemotherapeutic challenge, can be modeled by incorporation of bacilli into self-assembled lipid-inorganic nanostructures. This model combines the ability for in vitro study and growth condition modulation, with the potential for in vivo implantation and infection. We will generate a new in vitro model for high throughput screening for targets of, and drugs that can eliminate latent TB, to complement the existing complex in vivo models and al- low this field to move forward. Specific Aim 1 Define the conditions for optimal lipid-inorganic nanostructure-encasement of mycobacteria and its effects upon mycobacterial resistance to drugs. Specific Aim 2 Determine the changes in mycobacterial metabolism occurring upon encasement in lipid- inorganic nanostructures that result from non-replicative persistence, and drive in vitro survival and latency. Specific Aim 3 Demonstrate that lipid-inorganic nanostructure-encased mycobacteria represent valid models of latency by showing their infectivity in mice, even after extended periods of time after assembly. PUBLIC HEALTH RELEVANCE: Public Health Relevance We need to understand the way that tuberculosis is able to exist in a latent state because it is present in 2 billion people worldwide and reactivates into an active form in a significant percentage of cases. Clearing this 'reservoir' will be an essential component of an eventual eradication strategy. Although there are animal models of latency, there is no good model of in vitro latency, yet we need to have such an in vitro model so that we can understand how to attack it, and also to screen drugs with. We have developed a unique nanostructured model that mimics the extreme non-replicative persistence of latency, and want to test how effective it might be as a tool in the battle against TB.
描述(由申请人提供):结核分枝杆菌潜伏存在于20亿人中,由于再活化,代表了结核病(TB)的主要储存库,但潜伏杆菌的状态仍然是一个谜。为了根除结核病,我们需要了解潜伏期并开发用于药物筛选的体外模型。在这个跨学科的项目中,我们将微生物结核病研究与纳米技术和新材料相结合。最近的出版物证明了混合脂质-无机纳米结构的细胞定向组装的独特现象,其驱动独特的非复制性持久性,并保护细菌并显著延长生存力。我们发现这些相同的结构可以使用分枝杆菌形成,并且它们显示出潜伏期的高度扩展的生存能力特征。我们假设潜伏性TB的持久性及其对化疗挑战的抗性可以通过将杆菌并入自组装脂质无机纳米结构来建模。该模型结合了体外研究和生长条件调节的能力,以及体内植入和感染的潜力。我们将建立一种新的体外模型,用于高通量筛选可以消除潜伏性TB的靶标和药物,以补充现有的复杂体内模型,并使该领域向前发展。具体目标1确定最佳脂质-无机纳米结构包裹分枝杆菌的条件及其对分枝杆菌耐药性的影响。具体目标2确定包裹在脂质无机纳米结构中时因非复制持续性而发生的分支杆菌代谢变化,并驱动体外存活和潜伏期。具体目标3证明脂质无机纳米结构包裹的分枝杆菌通过显示其在小鼠中的感染性代表有效的潜伏期模型,即使在组装后延长的时间段之后。 公共卫生相关性:我们需要了解结核病能够以潜伏状态存在的方式,因为它存在于全世界20亿人中,并在很大比例的病例中重新激活为活动形式。清除这一“水库”将是最终根除战略的一个重要组成部分。虽然有潜伏期的动物模型,但没有很好的体外潜伏期模型,但我们需要有这样一个体外模型,以便我们能够了解如何攻击它,并筛选药物。我们开发了一种独特的纳米结构模型,它模仿了极端的非复制性延迟持久性,并希望测试它作为对抗结核病的工具的有效性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

GRAHAM S TIMMINS其他文献

GRAHAM S TIMMINS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('GRAHAM S TIMMINS', 18)}}的其他基金

Rifampin potentiation in NTM
利福平在 NTM 中的增强作用
  • 批准号:
    9908969
  • 财政年份:
    2020
  • 资助金额:
    $ 22.5万
  • 项目类别:
Reversing Isoniazid Resistance By Isotopic Substitution
通过同位素替代逆转异烟肼耐药性
  • 批准号:
    9347156
  • 财政年份:
    2017
  • 资助金额:
    $ 22.5万
  • 项目类别:
Pyrazinamide Breath Test for TB
吡嗪酰胺呼气试验检测结核病
  • 批准号:
    8870819
  • 财政年份:
    2015
  • 资助金额:
    $ 22.5万
  • 项目类别:
Breath Test for Pseudomonas aeruginosa in CF
CF 中铜绿假单胞菌呼气试验
  • 批准号:
    7571290
  • 财政年份:
    2009
  • 资助金额:
    $ 22.5万
  • 项目类别:
Breath Test for Pseudomonas aeruginosa in CF
CF 中铜绿假单胞菌呼气试验
  • 批准号:
    7895581
  • 财政年份:
    2009
  • 资助金额:
    $ 22.5万
  • 项目类别:
Nanostructured in vitro TB latency model
纳米结构体外结核潜伏期模型
  • 批准号:
    7737798
  • 财政年份:
    2009
  • 资助金额:
    $ 22.5万
  • 项目类别:
Molecular Surrogate for Melanoma Prevention
预防黑色素瘤的分子替代品
  • 批准号:
    7383595
  • 财政年份:
    2007
  • 资助金额:
    $ 22.5万
  • 项目类别:
Molecular Surrogate for Melanoma Prevention
预防黑色素瘤的分子替代品
  • 批准号:
    7501411
  • 财政年份:
    2007
  • 资助金额:
    $ 22.5万
  • 项目类别:
MOLECULAR IMAGING OF MELANOMA BY EPR
通过 EPR 进行黑色素瘤分子成像
  • 批准号:
    7048244
  • 财政年份:
    2006
  • 资助金额:
    $ 22.5万
  • 项目类别:
Antimycobacterial NO from KatG Activation of Isoniazid
KatG 激活异烟肼的抗分枝杆菌 NO
  • 批准号:
    7230267
  • 财政年份:
    2006
  • 资助金额:
    $ 22.5万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 22.5万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 22.5万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 22.5万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 22.5万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 22.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 22.5万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 22.5万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 22.5万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 22.5万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 22.5万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了